Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
With
HealthCore, Inc.
Using US claims data from the HealthCore Integrated Research Environment, COPD patients ≥40 years old initiating BFC or tiotropium between 3/1/2009-2/28/2012 and considered at risk for a future exacerbation were identified and followed for 12 months.
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Continuous health plan enrollment for 12 months before and after index Rx
At least one prescription fill for BFC or tiotropium bromide during intake period, and naive to ICS/LABA combination or LAMA therapies in year prior to first prescription claim.
COPD diagnosis, and aged 40 years of age at time of first prescription
At risk population for COPD exacerbations
You may not be if
ICS/LABA combination or LAMA therapy during pre-index period
Patients with prescription claim for budesonide/formoterol and tiotropium bromide on the same day
Patients diagnosed with cancer
Patients with long-term OCS medication use during pre-index period
Clareo Health | Comparative Effectiveness of Symbicort vs. Spiriva Among COPD Patients
